{"id":482817,"date":"2021-04-27T16:33:17","date_gmt":"2021-04-27T20:33:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/"},"modified":"2021-04-27T16:33:17","modified_gmt":"2021-04-27T20:33:17","slug":"dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/","title":{"rendered":"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)"},"content":{"rendered":"

<\/p>\n

DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)<\/b><\/p>\n

Study initiated with Researchers from the Stanford University School of Medicine<\/i><\/p>\n

LA JOLLA, Calif.–(BUSINESS WIRE<\/a>)–DermTech<\/a>, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with researchers from the Stanford University School of Medicine, led by principal investigator, Kavita Sarin, MD, PhD, on research titled, \u201cA Study of Longitudinal Non-Invasive Cytokine Monitoring in Patients with Hidradenitis Suppurativa.<\/i>\u201d This collaboration highlights DermTech\u2019s commitment to using precision genomics and personalized dermatology approaches to improve the understanding of dermatological diseases.\n<\/p>\n

\nHidradenitis suppurativa (\u201cHS\u201d), also known as acne inversa, is a chronic skin condition characterized by recurrent swollen and painful lesions in the armpit (axillae), groin, anal, and breast regions. The primary etiology of HS is not well defined, and consequently in many cases it can take more than seven years from disease onset to properly diagnose HS. The three-year study will utilize DermTech\u2019s non-invasive sample collection and precision genomics platform to identify and longitudinally evaluate biomarkers in patients with HS. Specifically, this study will use DermTech\u2019s proprietary technology to phenotypically characterize HS, identify potential subsets of HS, and aid in treatment decisions.\n<\/p>\n

\n\u201cHidradenitis suppurativa is a debilitating skin condition associated with a significant psycho-social burden and an unmet diagnostic and therapeutic need. We are excited to collaborate with the team at Stanford to longitudinally evaluate biomarkers that are associated with disease flares in HS and are committed to improving our understanding of HS as we strive to use precision and personalized dermatology approaches to positively impact those suffering from the disease,\u201d said Michael Howell, PhD, DermTech\u2019s chief scientific officer.\n<\/p>\n

About DermTech:<\/b><\/p>\n

\nDermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech\u2019s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech\u2019s investor relations site at: www.dermtech.com<\/a>.\n<\/p>\n

Forward-Looking Statements:<\/b><\/p>\n

\nThis press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech\u2019s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech\u2019s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech\u2019s tests; (4) the reimbursement of DermTech\u2019s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech\u2019s products; (6) DermTech\u2019s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech\u2019s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and\/or competitive factors; and (9) other risks and uncertainties included in (x) the \u201cRisk Factors\u201d section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the \u201cSEC\u201d), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210427005185\/en\/<\/a><\/span><\/p>\n

\nDermTech
\n
Sarah Dion
\n
sdion@dermtech.com
\n<\/a>
858.450.4222\n<\/p>\n

\nCrowe PR
\n
Sarah Gallagher
\n
sgallagher@crowepr.com
\n<\/a>
224.406.4709\n<\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Genetics Biotechnology Other Health Health University Pharmaceutical Science Education<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) Study initiated with Researchers from the Stanford University School of Medicine LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with researchers from the Stanford University School of Medicine, led by principal investigator, Kavita Sarin, MD, PhD, on research titled, \u201cA Study of Longitudinal Non-Invasive Cytokine Monitoring in Patients with Hidradenitis Suppurativa.\u201d This collaboration highlights DermTech\u2019s commitment to using precision genomics and personalized dermatology approaches to improve the understanding of dermatological diseases. Hidradenitis suppurativa (\u201cHS\u201d), also known as acne inversa, is a chronic skin condition characterized by recurrent swollen and painful lesions in the armpit … <\/p>\n

Continue reading “DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-482817","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) Study initiated with Researchers from the Stanford University School of Medicine LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with researchers from the Stanford University School of Medicine, led by principal investigator, Kavita Sarin, MD, PhD, on research titled, \u201cA Study of Longitudinal Non-Invasive Cytokine Monitoring in Patients with Hidradenitis Suppurativa.\u201d This collaboration highlights DermTech\u2019s commitment to using precision genomics and personalized dermatology approaches to improve the understanding of dermatological diseases. Hidradenitis suppurativa (\u201cHS\u201d), also known as acne inversa, is a chronic skin condition characterized by recurrent swollen and painful lesions in the armpit … Continue reading "DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-27T20:33:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)\",\"datePublished\":\"2021-04-27T20:33:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/\"},\"wordCount\":840,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/\",\"name\":\"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-04-27T20:33:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/","og_locale":"en_US","og_type":"article","og_title":"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) - Market Newsdesk","og_description":"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) Study initiated with Researchers from the Stanford University School of Medicine LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with researchers from the Stanford University School of Medicine, led by principal investigator, Kavita Sarin, MD, PhD, on research titled, \u201cA Study of Longitudinal Non-Invasive Cytokine Monitoring in Patients with Hidradenitis Suppurativa.\u201d This collaboration highlights DermTech\u2019s commitment to using precision genomics and personalized dermatology approaches to improve the understanding of dermatological diseases. Hidradenitis suppurativa (\u201cHS\u201d), also known as acne inversa, is a chronic skin condition characterized by recurrent swollen and painful lesions in the armpit … Continue reading \"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-27T20:33:17+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)","datePublished":"2021-04-27T20:33:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/"},"wordCount":840,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/","name":"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-04-27T20:33:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005185r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-to-collaborate-on-longitudinal-study-on-hidradenitis-suppurativa-hs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=482817"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482817\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=482817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=482817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=482817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}